Novavax Inc vs Raytheon Technologies Corp — how do they compare? Novavax Inc trades at $7.95 (market cap $1.30B), while Raytheon Technologies Corp trades at $223.5 (market cap $302.06B). The key difference: Raytheon Technologies Corp is far larger — about 232.4× Novavax Inc's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RTX | |
|---|---|---|
Market Cap | $1.30B | $302.06B |
Sector | Health | Industrials |
52-Week High | $11.19 | $224.12 |
52-Week Low | $6.22 | $151.75 |
Enterprise Value | $879.40M | $332.61B |
Dividend Yield | — | 1.3% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →